PROVIDENCE, R.I., Sept. 2, 2026 /PRNewswire/ -- Laser Research Optics has introduced a full line of CO2 beam delivery optics for use with lasers in the metal cutting, welding, engraving, plastic, textile, and medical industries.

Laser Research Beam Delivery Optics are optimized for 10.6 µm 25 to 200 Watt lasers and are offered in 0.6" to 3." dia. sizes with reflectivities up to 99%. Included are beam combiners and splitters, ZnSe output couplers or front mirrors, silicon and molybdenum turning mirrors, silicon and copper phase retardation reflectors, and germanium end- and zero phase-reflectors.

Phase retarders and reflectors are available in a variety of thicknesses with different coatings to achieve the desired phase shift and the output couplers provide reflectivity tolerances of ±1%. Laser Research Beam Delivery Optics are approved for OEMs and end-users.

Laser Research Beam Delivery Optics are priced according to type, size, and quantity and are in-stock for immediate delivery.

For more information contact:

Laser Research Optics

A Division of Meller Optics, Inc.

Scott Rouillard, Sales Mgr.

120 Corliss St.

Providence, RI 02904

(888) 239-5545 FAX (401) 331-4004

e-mail: scott@laserresearch.net

www.laserresearch.net 

SOURCE Laser Research Optics

Share this article

New high-transmission privacy with patented technology delivers about 12% higher transmission than standard privacy film; new on-demand platform cuts a single Eyesafe film to fit nearly any device

MINNEAPOLIS and BERLIN, Sept. 2, 2026 /PRNewswire/ -- Eyesafe, the global leader in display health and screen protection technologies, today introduced two additions to its screen protection platform at IFA 2026: Eyesafe® HT Privacy, a high-transmission privacy screen technology, and Eyesafe® Universal, an on-demand screen protection platform precision-cut to fit a wide range of devices.

Eyesafe HT Privacy: Privacy. Brighter.

Privacy screens protect sensitive information in public spaces - but have always demanded a familiar trade: reduced display brightness.

Eyesafe HT Privacy is engineered to improve that equation. In Eyesafe laboratory measurements across leading smartphones and industry reference displays, HT Privacy delivered 74–75% average light transmission versus 66.3% for standard privacy film - about 12% higher - while maintaining effective side-angle privacy and showing no visible color shift on any display tested.*

"Privacy screens have historically asked people to give up part of the display experience," said Justin Barrett, CEO of Eyesafe. "HT Privacy improves that equation — a brighter head-on picture, side-angle privacy maintained, and patented Eyesafe protection built in."

Eyesafe Universal: One film. Every screen.

Conventional screen protection programs require separate pre-cut inventory for every device model. Eyesafe Universal replaces that wall of SKUs with a single film platform, precision-cut on demand for compatible smartphones, tablets and other displays — at the retail counter or in the service channel, including devices released after the film ships.

Eyesafe technology is integrated into the film material, maintaining clarity, touch response and a self-healing surface. Eyesafe Universal is available to partners now through evaluation programs, with volume production scaling through 2027.

Both technologies are available to brands and retailers in CPF or RPF technology variants. Eyesafe is meeting partners at IFA 2026 in Berlin, September 3–6. More: eyesafe.com/IFA2026, eyesafe.com/htprivacy and eyesafe.com/universal.

About Eyesafe

Eyesafe is the global leader in display health, screen protection and advanced light-management technologies, with more than 100 patents and technology shipped in over 350 million devices worldwide.

* Eyesafe measurement, August 2026: average transmittance 400–780nm, Eyesafe HT Privacy vs standard privacy film, measured across leading smartphones and industry reference displays; color difference ΔE2000 ≤1.9 on all displays tested. As with all privacy filters, brightness is reduced relative to an unprotected display.

SOURCE Eyesafe

Share this article

Tusker Acquires Fortress SRM to Expand Cybersecurity Services

Adds New Cybersecurity Expertise, 24/7 Security Operations Center and Ohio Valley Presence

CHICAGO, Sept. 2, 2026 /PRNewswire/ -- Tusker, a full-service technology solutions provider with clients across the country, today announced the acquisition of Fortress SRM, a Cleveland-based firm specializing in cybersecurity services. The acquisition adds nearly 50 cybersecurity professionals to the Tusker team, provides new security capabilities including 24/7 oversight, and expands Tusker's geographic footprint with a sixth regional hub.

Founded in 2018, Fortress SRM serves customers across Ohio, northern Michigan and Wisconsin with a team of approximately 50 cybersecurity professionals. Its capabilities span security consulting and advisory services, virtual CISO leadership, managed security, incident response and digital forensics, and a 24/7 Security Operations Center (SOC) that delivers around-the-clock threat detection, analysis and remediation support.

The acquisition is the latest step in a strategic expansion campaign that has grown Tusker from its roots as a Chicago-based IT hardware distributor to a full-stack technology provider with more than 400 employees and regional hubs in Chicago, Boston, Green Bay, Duluth, Eau Claire and now Cleveland.

It marks Tusker's fifth acquisition since 2017 and its first since unifying its portfolio companies under the Tusker brand earlier this year. Additional acquisitions are planned as the company continues building its geographic reach.

Expanding the Tusker Platform

The acquisition brings together two organizations with complementary strengths: Fortress SRM's deep cybersecurity expertise, Tusker's broader technology capabilities and geographic reach, and the high-touch service and trusted relationships that have been central to both organizations. It also advances a Tusker initiative to aggressively expand its services business.

"Fortress SRM brings exactly the kind of expertise and customer-centered culture that has defined every company we have acquired over the last nine years," said Matt Zafirovski, CEO of Tusker. "This acquisition expands our cybersecurity team and related service capabilities, plants a flag for Tusker in the Ohio Valley, and strengthens our ability to be a trusted technology partner across the customer's entire IT environment."

The transaction also provides significant benefits to Fortress SRM's cybersecurity customers.

"Many of our cybersecurity clients want a trusted partner who can support all of their IT needs, from desktops, servers and networks to technology planning, modernization and managed services," said Jess Walpole, President of Fortress SRM. "Joining forces with Tusker gives them that convenience, along with a larger team and the same personal service they have come to expect from us."

About Tusker

Tusker is a mid-market IT solutions provider that blends a broad portfolio of advisory, professional, managed and lifecycle technology solutions with a focus on building long-term client partnerships through a combination of IT expertise and highly personalized service. The firm operates from multiple regional hubs, serving clients ranging from local organizations to national brands. For more information, visit www.tuskerco.com.

SOURCE ACP/Tusker

Share this article

Company Maintains Steady Revenue Momentum Following Recent Acquisitions

DUBAI, UAE, Sept. 2, 2026 /PRNewswire/ -- Robo.ai Inc. (Nasdaq: AIIO) ("Robo.ai" or the "Company"), a UAE-based Nasdaq-listed company, today provided an update on its revenue performance following its acquisition of Quantum Core Capital Limited ("QC Capital"). This update reflects the Company's continued progress in expanding its businesses and integrating recently acquired operations as it builds toward establishing technology-empowered platforms spanning artificial intelligence, robotics & smart mobility, advanced manufacturing, and digital assets & capital.

For the three-month period from June through August 2026, Robo.ai recorded total revenue of over US$180 million, primarily contributed by QC Capital, which the Company acquired on June 15, 2026. Since the acquisition, the Company has sustained steady operations and continued to deliver revenue, with the new business contributing meaningfully to overall growth.

"Since completing the acquisition in June, we have seen steady operating momentum and continued revenue contribution from our acquired business," said Benjamin Zhai, Chief Executive Officer of Robo.ai. "Our overall revenue performance over the past several months gives us greater confidence in the progress we are making and provides a solid foundation for our next stage of development. We remain focused on disciplined execution and integration, while continuing to strengthen our business and build on this momentum as we work toward sustainable growth."

The revenue information presented in this press release is preliminary and unaudited and has not been reviewed by the Company's independent registered public accounting firm. The information may be subject to adjustment in connection with the Company's financial closing and review procedures.The consideration shares for the QC Capital acquisition are subject to a phased, revenue-linked release mechanism, as previously disclosed on Form 6-K on June 18, 2026.

About Robo.ai Inc.

Robo.ai Inc. (Nasdaq: AIIO), headquartered in Dubai, United Arab Emirates, is a Nasdaq-listed technology group building intelligent infrastructure across four platforms: artificial intelligence; robotics and smart mobility; advanced manufacturing; and digital assets and capital. Its industrial group, Alif Holding, is dedicated to building intelligent industries through the development, integration and manufacturing of AI systems, serving government, public sector and mission-critical domains. Through its subsidiary Neurovia AI, the Company develops AI software and visual data infrastructure. Quantum Core Capital ("QC Capital"), its AI-powered deep-tech holding and venture-building platform, incubates, invests in and operates businesses across artificial intelligence, robotics, digital infrastructure and the next-generation digital economy.

Forward-Looking Statements

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "targets," "likely to," "challenges," and similar statements. Robo.ai may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Robo.ai's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Robo.ai's strategies, future business development, and financial condition and results of operations; Robo.ai's limited operating history in its current business; Robo.ai's ability to generate positive cash flow and profits; Robo.ai's ability to compete successfully; Robo.ai's ability to build its brand and withstand negative publicity; and changes in customer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Robo.ai's filings with the SEC. All information provided in this press release is as of the date of this press release, and Robo.ai does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

For investors:

Robo.ai Inc. Investor Relations

E-mail: ir@roboai.group

For media:

Robo.ai Inc. Corporate Communications

E-mail: pr@roboai.group

Website: www.roboai.group

SOURCE Robo.ai Inc.

Share this article

DELRAY BEACH, Fla., Sept. 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the global Pilot-Operated Gas Regulators Market size is projected to grow from USD 0.39 billion in 2026 to USD 0.52 billion by 2031 at a compound annual growth rate (CAGR) of 5.6% during the forecast period.

Browse over 150 market data tables and 60 figures spread through 310 pages and an in-depth TOC on 'Pilot-Operated Gas Regulators Market – Global Forecast to 2031.'

The global market for pilot-operated gas regulators is witnessing robust growth driven by several key factors. The expansion of natural gas infrastructure and modernization of pipelines are crucial components facilitating this trend. Additionally, rising gas consumption levels and stringent safety regulations regarding pressure management are further propelling the adoption of these regulators. As a result, a significant uptick in demand is observed, which aligns with the industry's evolving technical and safety standards. Pilot-operated regulators are increasingly deployed as high-accuracy pressure control solutions across gas transmission and distribution networks, city gas distribution systems, gas processing facilities, industrial plants, and power-generation applications. Demand is also supported by the replacement of aging pressure regulation equipment, expansion of LNG and gas pipeline infrastructure, and increasing adoption of automated and remotely monitored pressure control systems. North America, Europe, and Asia Pacific remain important markets, supported by extensive gas infrastructure and ongoing investments in network modernization, while emerging gas distribution and industrialization projects in Asia Pacific and the Middle East are creating additional opportunities for market growth.

Pilot-Operated Gas Regulators Market Size & Forecast:

- Market Size Available for Years: 2022–2031

- 2025 Market Size: USD 0.37 billion

- 2031 Projected Market Size: USD 0.52 billion

- CAGR (2026–2031): 5.6%

Pilot-Operated Gas Regulators Market Trends & Insights:

- Asia Pacific is expected to register the highest CAGR of 6.6% in the Pilot-Operated Gas Regulators Market during the forecast period.

- High-pressure pilot-operated gas regulators are likely to hold the largest market share, by pressure, throughout the forecast period.

- By installation type, the new installation segment is expected to register a higher CAGR of 6.1% during the forecast period.

- By installation location, the onshore segment is expected to register a higher CAGR of 5.7% during the forecast period.

- By end-use industry, the gas utilities segment is likely to hold the largest market share during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142621644

By installation type, the new installation segment is expected to record a faster growth rate in the Pilot-Operated Gas Regulators Market during the forecast period.

Growth is supported by the expansion of natural gas transmission and distribution networks, new city gas distribution projects, gas processing facilities, LNG infrastructure, and industrial gas applications. New installations provide operators with opportunities to deploy modern pilot-operated regulators with improved pressure accuracy, higher flow capacity, integrated safety shutoff, and remote monitoring capabilities from the initial design stage. The retrofit segment, however, remains significant as utilities and pipeline operators increasingly replace aging mechanical pressure regulation equipment with advanced pilot-operated systems. Retrofit projects enable operators to improve pressure stability, safety, and operational efficiency while extending the useful life of existing pressure reduction stations and avoiding the higher costs associated with complete infrastructure replacement. Demand is particularly strong in mature gas markets such as North America and Europe, where substantial installed gas infrastructure requires periodic modernization and replacement. Manufacturers are also developing regulator designs capable of operating with hydrogen-blended gas and other evolving gas compositions, creating additional opportunities as gas networks transition toward lower carbon fuels.

By end-use industry, the gas utilities industry is expected to account for the largest market share over the forecast period.

Gas utilities are the primary users of pilot-operated regulators because these devices are widely deployed across natural gas transmission, distribution networks, and city-gate stations. They play a crucial role in mitigating elevated inlet pressures to achieve regulated downstream levels, while ensuring constant gas flow even in the face of supply pressure variations and changes in customer demand. The expansion and modernization of natural gas distribution infrastructure primarily drives growth in the gas utilities segment. Developing markets are investing in new pipelines and city gas distribution networks to extend natural gas access to residential, commercial, transportation, and industrial customers. At the same time, mature gas markets are replacing aging regulators and upgrading pressure-reduction stations to improve network reliability, safety, and operational efficiency. These replacement and modernization activities create recurring demand for pilot-operated regulators. Gas utilities are also facing growing pressure to reduce methane emissions and improve energy efficiency across distribution networks. This is encouraging the adoption of low-bleed and low-emission regulator technologies that minimize gas losses during normal operation and maintenance. In addition, the transition toward hydrogen blending and renewable gases is creating new requirements for regulators capable of handling changes in gas composition, pressure, and flow characteristics.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=142621644

Asia Pacific is likely to be the fastest-growing region in the Pilot-Operated Gas Regulators Market during the forecast period.

Asia Pacific is expected to be the fastest-growing region in the Pilot-Operated Gas Regulators Market during the forecast period, supported by rapid expansion of natural gas transmission and distribution infrastructure, increasing urbanization, industrialization, and the development of city gas distribution networks. China, India, Japan, South Korea, and Southeast Asian countries are investing in gas pipelines, LNG terminals, gas processing facilities, and industrial gas infrastructure, creating substantial demand for reliable pressure regulation equipment. The region is also witnessing increased replacement of aging pressure control systems and adoption of automated regulators as utilities seek to improve network safety, pressure stability, and operational efficiency. China and India are particularly important growth markets because of expanding natural gas consumption and ongoing investments in pipeline connectivity and city gas distribution. India's expansion of the City Gas Distribution network and natural gas infrastructure is increasing the requirement for pressure-reduction and regulation stations across residential, commercial, transportation, and industrial applications. Similarly, China is expanding its natural gas pipeline network and LNG infrastructure, supporting demand for high-capacity pressure management equipment.

Top Companies in Pilot-operated Gas Regulators Industry:

The Pilot-operated Gas Regulators Industry include Emerson (US), Honeywell International Inc. (US), Pietro Fiorentini S.P.A (Italy), Baker Hughes (US), Dresser Utility Solutions (US), Nirmal Industrial Controls Pvt Ltd. (India), Cavagna Group S.P.A (Italy), Valvitalia (Italy), Axis Solutions Limited (India), Gascat Ind. E com. ltda (Brazil), Cashco (US), Oxford Flow (UK), Flow Metering Technology (India), SPECS VALVE (China), and Gasteh (Serbia). These companies compete through broad pressure regulation portfolios, high-pressure and high-capacity regulator designs, advanced pilot technologies, safety shutoff solutions, and customized pressure control systems for gas transmission, distribution, industrial, and energy applications.

For more information, Inquire Now!

Related Reports:

Industrial Gas Regulators Market

Get access to the latest updates on Pilot-operated Gas Regulators Companies and Pilot-operated Gas Regulators Industry

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.

DER PERFEKTE URLAUB

Alte Freunde, neue Geheimnisse und jede Menge Malle!

Plakat und Trailer ab sofort online!

München (ots)

Reif für den Urlaub mit den besten Freunden und bereit für die nächste Eskalationsrunde? Dann nichts wie los und schon einmal den neuen Trailer von DER PERFEKTE URLAUB klicken: Link zum Trailer

Das Star-Ensemble ist zurück! Nach DAS PERFEKTE GEHEIMNIS kommt DER PERFEKTE URLAUB. Aber wer traut nach dem Handy-Spiel eigentlich noch wem? Ein Kurztrip der Clique endet unfreiwillig in einem spanischen Ferienclub. Doch der perfekte Urlaub eskaliert.

Nach dem Kinohit DAS PERFEKTE GEHEIMNIS mit mehr als 5,3 Mio. verkauften Kinotickets versammeln die Filmemacher*innen Bora Dagtekin und Lena Schömann auch in DER PERFEKTE URLAUB einen prominenten Cast vor der Kamera: Erneut zählen Elyas M'Barek, Karoline Herfurth, Jessica Schwarz, Florian David Fitz, Jella Haase, Frederick Lau, Wotan Wilke Möhring sowie Emily Kusche zum bewährten Ensemble, das Unterstützung von Diana Amft als Carlottas (Karoline Herfurth) beste Freundin erhält. In weiteren Rollen sind David Korbmann, Maria Dragus, Daniel Zillmann, Caroline Maria Frier, Inez Bjørg David und Jan van Weyde ab dem 22. Oktober im Verleih der Constantin Film im Kino zu sehen.

Zum Inhalt:

Mehr als fünf Millionen Deutsche reisen jedes Jahr nach Mallorca. Leo (Elyas M'Barek), Pepe (Florian David Fitz), Rocco (Wotan Wilke Möhring) und Simon (Frederick Lau) nehmen sich ebenfalls eine Auszeit im 17. Bundesland. Erst mal Wunden lecken, sich sammeln, Abstand gewinnen. Seit dem entgleisten Handy-Spiel ist nichts mehr, wie es war. Guter Plan. Blöd nur, dass aus dem entspannten Jungs-Trip nichts wird: Eva (Jessica Schwarz), Carlotta (Karoline Herfurth) und ihre beste Freundin Maus (Diana Amft) haben sich in derselben Villa auf Malle einquartiert. Auf die harte Tour muss die dysfunktionale Clique herausfinden, was von Freundschaft, Vertrauen und Liebe überhaupt noch übrig ist. Und als die Finca in Flammen aufgeht und die Freunde in einem Gute-Laune-Clubhotel stranden, bringen alte Wunden und neue Enthüllungen die Fassaden endgültig zum Bröckeln. Bald steht nicht nur jede einzelne Beziehung, sondern die gesamte Freundschaft auf dem Spiel. Kann Leo nach seiner SMS-Affäre Carlottas Vertrauen zurückgewinnen? Eva hat nicht nur Stress mit ihrer Teenager-Tochter Sophie (Emily Kusche), sondern auch mit ihrem Mann. Beide ahnen, dass sie sich gegenseitig etwas verschweigen, doch mit Roccos Zweithandy hatte Eva nicht gerechnet. Pepe, frisch geoutet, wünscht sich mehr Support von seinen Hetero-Kumpels, während er sich selbst noch nicht ganz gefunden hat. Und Simon ist der Charmeur geblieben, der jede Konsequenz wegwitzelt. Doch als seine Ex-Freundin Bianca (Jella Haase) auftaucht, geht es ans Eingemachte ... VAMOS A LA DRAMA!

DER PERFEKTE URLAUB ist eine Constantin Film Produktion und wurde mit Mitteln des FilmFernsehFonds Bayern (FFF), der Filmförderanstalt (FFA) und des Deutschen Filmförderfonds (DFFF) gefördert. Der Film erhielt das Green Motion Label. Das Drehbuch stammt von Bora Dagtekin, der auch Regie führte. Produzentin ist Lena Schömann, Producerin Nicole Springstubbe. Executive Producer ist Oliver Berben.

Kinostart: 22. Oktober 2026 im Verleih der Constantin Film

Darsteller*innen: Elyas M'Barek, Karoline Herfurth, Jessica Schwarz, Florian David Fitz, Jella Haase, Frederick Lau, Diana Amft, Wotan Wilke Möhring, Emily Kusche, David Korbmann, Paul Ahrens, Maria Dragus, Daniel Zillmann, Caroline Maria Frier, Jan van Weyde, Inez Bjørg David u.v.m.

Drehbuch & Regie: Bora Dagtekin

Produzentin: Lena Schömann

Producerin: Nicole Springstubbe

Executive Producer: Oliver Berben

Erstes Pressematerial zum Film steht unter https://presse.constantin.film zum Download zur Verfügung.

Wenn Sie weitere Informationen wünschen, wenden Sie sich bitte an die betreuende Agentur:

Pressekontakt:

JUST PUBLICITY GmbH

(TV-, Print-, Hörfunk-PR)

Regine Baschny, Sabrina Wintersberger & Saskia Wach

Tel. 089 20 20 82 60

info@just-publicity.com

JUST PUBLICITY ONLINE GmbH

(Online PR)

Nina Schattkowsky & Mona Seybold

Tel. 030 5093134 20

info@just-publicity-online.com

Original-Content von: Constantin Film, übermittelt durch news aktuell

TwinDEX Introduces a Scalable Path from Robot-Free Data Collection to Real-World Dexterous Manipulation

SHENZHEN, China, Sept. 2, 2026 /PRNewswire/ -- Today, X Square Robot introduced TwinDEX, a pair of co-designed, three-finger, nine-DoF dexterous manipulation interface: one wearable for data collection, one for robot deployment. Together with synchronized sensing, a data processing pipeline, and a policy training workflow, the manipulation interface creates a direct and scalable path from robot-free data collection to real-world dexterous manipulation.

The data problem behind dexterous manipulation

Robots operating in open environments must do much more than pick and place objects. They need to twist, insert, pour, open latches, use tools, handle narrow spaces, and adjust through contact. These tasks depend not only on where the hand moves, but also on how the fingers make contact, when force is applied, and how the system corrects small errors in a closed loop.

Training data remains a major bottleneck. On-robot teleoperation produces demonstrations that match the target hardware, but it is expensive and difficult to scale: Teleoperation occupies the robot, requires a prepared workspace, and often depends on a skilled operator. Robot-free collection is easier to scale, but it can create an embodiment gap. If the collection device and the robot differ in kinematics, fingertip geometry, visual appearance, or timing, a demonstration may lose contact relationships that made the original action successful.

TwinDEX is designed to narrow this gap through the co-design of its data-collection and deployment hardware. It pairs a wearable data-collection device with a closely matched robotic end effector. Both share a three-finger, nine-degree-of-freedom architecture, comprising seven active and two passive degrees of freedom.

The design is built around three principles:

Dexterity. The three-finger configuration supports stable power grasps, precise pinches, multi-point contact, twisting, and tool usage. The team evaluated different hardware configurations using a benchmark covering several manipulation primitives. Within the current task set, seven active degrees of freedom provided the best balance among dexterity, mechanical complexity, cost, wearability, and reliability.

Consistency. The collection and deployment devices are aligned across the parts of the system that affect policy learning. They share corresponding kinematic chains, joint axes, link proportions, contact geometry, surface materials, visual appearance, and sensor placement. This allows measured finger states to map directly to the robot joint space without complex hand-to-robot retargeting.

Consistency also includes data accuracy and time. TwinDEX synchronizes multi-view RGB camera inputs, six-degree-of-freedom wrist poses, finger joint states, and fingertip tactile signals. The team measures delays across sensing, inference, and execution so that the observation-action relationship seen during training better matches the one experienced during deployment.

Scalability. An operator can wear the exoskeleton and interact directly with real objects, without using a robot during data collection. One operator, one table, and one wearable system form a complete collection unit. This makes it possible to collect in offices, kitchens, workstations, and other real environments, while multiple operators can collect in parallel at different locations.

Direct interaction also preserves the operator's natural visual, contact, and proprioceptive feedback. This is especially useful for contact-rich tasks that are difficult to demonstrate through conventional teleoperation, where latency, limited viewpoints, and indirect force feedback can slow the operator or introduce unnatural motion.

Demonstrating long-horizon, contact-rich behavior

TwinDEX was evaluated on everyday manipulation tasks including cap twisting, sweeping with a broom and dustpan, sliding out and opening a book, releasing toolbox latches, and operating a syringe. These tasks test precise contact, tool control, small-target alignment, grasp transitions, and bimanual coordination. In the collection evaluation, TwinDEX delivered up to 5.3 times the effective throughput of on-robot teleoperation.

The system was then tested on a full standardized chemistry experiment executed autonomously in a single uncut run. Across 24 sub-actions, the robot had to open and stabilize containers, handle a thin scooper, use a rubber-bulb pipette, transfer liquids and solids, hold a nearly transparent glass rod against a beaker, guide a pour, switch tools, and coordinate both hands. Each stage required precise positioning and stable control through contact.

The chemistry demonstration shows that, when wearable collection and robotic deployment systems are closely aligned, a policy can learn fine-grained, long-horizon dexterous behavior from only a few hundred robot-free episodes, without any on-robot training data.

When data is no longer locked behind expensive robot hardware, when every demonstration is natively aligned with the target end effector, and when hardware, data, and models evolve together around the same closed loop, dexterous manipulation data can finally scale by orders of magnitude. TwinDEX is building exactly that path: one that can be replicated, measured, and continuously improved.

Project link: https://x2robot.com/en/pages/twindex

For more information, visit https://x2robot.com/

About X Square Robot

X Square Robot focuses on developing its own general-purpose embodied AI models and robotic hardware. As a leading Chinese company in the field, it has pioneered the deployment of general-purpose embodied AI in real-world settings such as homes and logistics.

SOURCE X Square Robot

Share this article

SAN ANTONIO, Sept. 2, 2026 /PRNewswire/ -- Operation Homefront® is proud to announce that nominations are now open for the 19th annual Military Child of the Year® Award, its signature program recognizing the resilience, leadership, and achievements of America's military children.

Each year, this prestigious award recognizes seven outstanding young individuals, one from each branch of the armed forces — Army, Marine Corps, Navy, Air Force, Space Force, Coast Guard, and National Guard. Eligible nominees must be between 13 and 18 years old, be legal dependents of a service member or military retiree, and demonstrate a commitment to excellence in areas such as academics, civic leadership, volunteerism, athletics, and the arts. Nominations will be accepted through December 1, 2026.

Behind every military family's service and sacrifice are children who regularly adjust to new communities, schools, and circumstances while continuing to thrive and give back. The Operation Homefront Military Child of the Year Award celebrates those who have made a meaningful impact through their contributions, determination, and involvement in their schools and communities despite these challenges. The 2026 recipients exemplify the caliber of young people recognized through this program. Collectively, the seven award recipients contributed more than 4,800 volunteer hours in the year leading up to their nominations and experienced a combined 35 military moves. Their achievements and commitment to others embody the tenacious spirit of the military community.

"Each of our nation's 1.6 million military children carries a story of strength, sacrifice, and service that deserves to be recognized," said retired Rear Adm. Alan Reyes, President and CEO of Operation Homefront. "Having experienced military life as a child and having raised two daughters in a military family, I understand the challenges and uncertainty these young people often face through circumstances beyond their control. Serving quietly behind the scenes, they demonstrate leadership, perseverance, and character well beyond their years. Their actions, accomplishments, and support for others make a lasting difference wherever military life takes them. The Operation Homefront Military Child of the Year Award shines a spotlight on their journeys and the contributions they make along the way."

All seven Operation Homefront Military Child of the Year Award recipients will be invited to attend the Military Child of the Year Awards Gala in April 2027 in Arlington, VA, where they will each receive $10,000, a laptop, and additional gifts from Operation Homefront's generous corporate partners.

Operation Homefront will provide airfare and lodging for each award recipient and two family members to attend the gala and spend a few days in the Washington, D.C. area.

Previous recipients have had the opportunity to meet Chairmen of the Joint Chiefs of Staff and their spouses, First Lady Michelle Obama, acclaimed broadcaster Lindsay Czarniak, and other distinguished leaders, celebrities, and philanthropists who have participated as guest speakers and entertainers.

"It felt meaningful being named Military Child of the Year, not just for the challenges I've faced as a military child, but for everything I've accomplished because of them. So much of my childhood happened behind the scenes, the hard mornings without my parents home, constant moves, deployments, and responsibilities that most kids never have to think about. Being acknowledged for those experiences makes me feel understood in a way that is rare. But what means even more is being recognized for the person I've become because of them – resilient, adaptable, responsible, and driven," said Victoria V., 2026 Military Child of the Year representing Coast Guard.

Anyone can nominate a military child—from family members and friends, to teachers, coaches, counselors, and clergy. Everyone is encouraged to recognize the outstanding military children in their lives. Visit operationhomefront.org/military-child-of-the-year to learn more and nominate a child for their respective branch award.

About Operation Homefront: Operation Homefront is a national nonprofit organization whose mission is to build strong, stable, and secure military and veteran families by improving their financial, emotional and social well-being. Recognized for superior performance by leading independent charity oversight groups, 85 percent of Operation Homefront expenditures go directly to programs that support tens of thousands of military families each year. Operation Homefront provides critical financial assistance, transitional and permanent housing, and family support services to prevent short-term needs from turning into chronic, long-term struggles. Thanks to the generosity of our donors and the support from thousands of volunteers, Operation Homefront proudly serves America's military families. For more information, visit OperationHomefront.org.

SOURCE Operation Homefront

Share this article

-NovaGo Therapeutics cierra una ronda de financiación Serie B de 30 millones de dólares para impulsar un estudio de prueba de concepto en lesiones agudas de la médula espinal

La ronda fue liderada por Neurimmune y Pureos, con la participación de inversores actuales y nuevos; complementada con financiación no dilutiva de la Fundación Suiza para Parapléjicos y Wings for Life - Fundación para la Investigación de la Médula Espinal.

SCHLIEREN, Suiza, 2 de septiembre de 2026 /PRNewswire/ -- NovaGo Therapeutics AG, una empresa de biotecnología en fase clínica que desarrolla fármacos biológicos anti-Nogo-A para enfermedades del sistema nervioso central, anunció hoy la finalización exitosa de una ronda de financiación Serie B de 24 millones de francos suizos (30 millones de dólares estadounidenses). La ronda fue liderada por Neurimmune y Pureos, con la participación de inversores actuales y nuevos. La financiación mediante capital se complementa con fondos no dilutivos de la Fundación Suiza para Parapléjicos y Wings for Life.

Los fondos obtenidos se utilizarán para impulsar el programa principal de NovaGo hacia un estudio de prueba de concepto (PoC) en pacientes con lesión medular aguda. El estudio es un ensayo completamente aleatorizado y doble ciego que recluta a 120 pacientes en centros de Alemania, España y Suiza.

La lesión medular sigue siendo un área con una gran necesidad médica no cubierta. Actualmente no existen opciones de tratamiento regenerativo aprobadas que restauren la función neurológica perdida, lo que deja a los pacientes y sus familias con perspectivas terapéuticas limitadas tras la lesión. El enfoque de NovaGo se centra en Nogo-A, una proteína que inhibe la regeneración de las fibras nerviosas y la neuroplasticidad en el sistema nervioso central, con el objetivo de permitir la recuperación funcional.

"Nos entusiasma ver que este programa avanza hacia esta etapa crucial de los ensayos clínicos, lo que nos acerca un paso significativo a un tratamiento muy necesario para los pacientes que viven con las consecuencias de una lesión medular", declaró el profesor Martin Schwab, director científico de NovaGo Therapeutics.

"Junto con NovaGo Therapeutics, estamos siendo pioneros en un enfoque innovador para el tratamiento de la lesión medular mediante un anticuerpo terapéutico totalmente humano diseñado para promover la regeneración nerviosa tras la lesión", declaró el profesor Roger M. Nitsch, presidente y consejero delegado de Neurimmune y miembro del Consejo de Administración de NovaGo Therapeutics. "Nos alientan los prometedores resultados de la Fase 1 con NG004 y esperamos avanzar en el programa de desarrollo clínico junto con NovaGo Therapeutics y nuestros coinversores, con el generoso apoyo de la Fundación Suiza para Parapléjicos y Wings for Life".

"Nos complace enormemente coliderar esta financiación y apoyar la siguiente etapa de desarrollo de NovaGo. El progreso y los resultados del estudio de Fase 1 en lesión medular son muy alentadores y vemos un gran potencial para ofrecer una nueva opción de tratamiento regenerativo para pacientes con lesión medular", afirmó Dominik Escher, socio gerente de Pureos Bioventures.

"Estamos profundamente agradecidos por el respaldo de nuestros inversores. El apoyo de Wings for Life y la Fundación Suiza para Parapléjicos también ha sido fundamental, haciendo posible esta crucial fase de desarrollo", declaró Stefan Moese, consejero delegado de NovaGo Therapeutics. "Su compromiso nos permite avanzar con el estudio de prueba de concepto y trabajar para ofrecer un tratamiento muy necesario a los pacientes afectados por las devastadoras consecuencias de las lesiones de la médula espinal".

Acerca de Pureos Bioventures

Pureos Bioventures es un fondo de capital de riesgo asesorado por la firma suiza de capital de riesgo Pureos Partners. Invierte exclusivamente en empresas privadas innovadoras de desarrollo de fármacos, con especial énfasis en la próxima generación de fármacos biológicos y formatos de medicamentos. Las empresas de la cartera del fondo se basan en la excelencia científica para desarrollar terapias en un amplio espectro de indicaciones, que incluye oncología, inmunología, oftalmología, enfermedades raras y neurociencia. Pureos ha formado un equipo con amplia experiencia en inversión, operaciones y clínica, que se esfuerza por mejorar la vida de los pacientes mediante el avance de tratamientos innovadores para enfermedades devastadoras. Para obtener más información, visite www.pureosbio.com.

Acerca de Neurimmune

Neurimmune es una empresa biofarmacéutica en fase clínica que desarrolla terapias con anticuerpos de última generación. La empresa es pionera en la eliminación de amiloide como un novedoso mecanismo terapéutico para tratar enfermedades del SNC y enfermedades relacionadas con la agregación de proteínas, como la enfermedad de Alzheimer, la esclerosis lateral amiotrófica y la cardiomiopatía por ATTR. Neurimmune descubrió el anticuerpo anti-ATTR cliramitug (anteriormente NI006, ALXN2220, Fase 3) para la cardiomiopatía por ATTR, el anticuerpo anti-SOD1 mal plegado AP-101 (Fase 2) para la ELA, el anticuerpo anti-Nogo-A NG004 (Fase 1) para la lesión de la médula espinal y el anticuerpo de cadena ligera anti-amiloide NI009 (preclínico) para la amiloidosis AL.

Acerca de NovaGo Therapeutics

NovaGo Therapeutics AG es una empresa de biotecnología en fase clínica que desarrolla nuevos fármacos biológicos anti-Nogo-A para promover la regeneración nerviosa y la recuperación funcional en pacientes con enfermedades y lesiones del sistema nervioso central, como lesiones de la médula espinal, accidentes cerebrovasculares y esclerosis múltiple progresiva secundaria. Fundada a partir de una investigación pionera sobre Nogo-A como inhibidor clave de la regeneración neuronal, NovaGo está impulsando su principal candidato a través del desarrollo clínico con el objetivo de ofrecer el primer tratamiento regenerativo para pacientes con lesión aguda de la médula espinal. NovaGo tiene su sede en Suiza.

Para más información, póngase en contacto con:

NovaGo Therapeutics AG

media@novagotx.com

www.novagotherapeutics.com 

Share this article

Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation.

SCHLIEREN, Switzerland, Sept. 2, 2026 /PRNewswire/ -- NovaGo Therapeutics AG, a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system, today announced the successful completion of a CHF 24 million (USD 30 million) Series B financing round. The round was led by Neurimmune and Pureos, with participation from existing and new investors. The equity financing is complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.

Proceeds from the financing will be used to advance NovaGo's lead program into a proof-of-concept (PoC) study in patients with acute spinal cord injury. The study is a fully randomized, double-blind trial enrolling 120 patients across sites in Germany, Spain, and Switzerland.

Spinal cord injury remains an area of high unmet medical need. There are currently no approved regenerative treatment options that restore lost neurological function, leaving patients and their families with limited therapeutic prospects following injury. NovaGo's approach targets Nogo-A, a protein that inhibits nerve fiber regeneration and neuroplasticity in the central nervous system, with the goal of enabling functional recovery.

"We are excited to see this program progress into this critical stage of clinical testing, bringing us a meaningful step closer to a much-needed treatment for patients living with the consequences of spinal cord injury," said Prof. Martin Schwab, Chief Scientific Officer of NovaGo Therapeutics.

"Together with NovaGo Therapeutics, we are pioneering a novel approach for the treatment of spinal cord injury using a fully human therapeutic antibody designed to promote nerve outgrowth after injury," said Prof. Roger M. Nitsch, President and Chief Executive Officer of Neurimmune and a member of the Board of Directors of NovaGo Therapeutics. "We are encouraged by the promising Phase 1 results with NG004 and look forward to advancing the clinical development program together with NovaGo Therapeutics and our co-investors, with generous support from the Swiss Paraplegic Foundation and Wings for Life."

"We are very pleased to co-lead this financing and support NovaGo's next stage of development. The progress and results from the Phase 1 study in spinal cord injury are very encouraging and we see great potential to provide a new regenerative treatment option for patients with spinal cord injury," said Dominik Escher, Managing Partner at Pureos Bioventures.

"We are deeply grateful for the backing of our investors. Support from Wings for Life and the Swiss Paraplegic Foundation have also been instrumental, helping make this crucial development phase possible." said Stefan Moese, Chief Executive Officer of NovaGo Therapeutics. "Their commitment allows us to move forward with the proof-of-concept study and work toward bringing a much-needed treatment to patients affected by the devastating consequences of spinal cord injury."

About Pureos Bioventures

Pureos Bioventures is a venture fund advised by the Swiss venture capital firm Pureos Partners. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund's portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients' lives by advancing innovative treatments for devastating diseases. For more information, please visit www.pureosbio.com.

About Neurimmune

Neurimmune is a clinical-stage biopharmaceutical company building next-generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered the anti-ATTR antibody cliramitug (formerly NI006, ALXN2220, Phase 3) for ATTR cardiomyopathy, the anti-misfolded SOD1 antibody AP-101 (Phase 2) for ALS, the anti-Nogo-A antibody NG004 (Phase 1) for spinal cord injury, and the anti-amyloid light chain antibody NI009 (preclinical) for AL amyloidosis.

About NovaGo Therapeutics

NovaGo Therapeutics AG is a clinical-stage biotechnology company developing novel anti-Nogo-A biologics to promote nerve regeneration and functional recovery in patients with diseases and injuries of the central nervous system, including spinal cord injury, stroke, and secondary progressive multiple sclerosis. Founded on pioneering research into Nogo-A as a key inhibitor of neuronal regeneration, NovaGo is advancing its lead candidate through clinical development with the goal of delivering the first regenerative treatment for patients with acute spinal cord injury. NovaGo is based in Switzerland.

For more information, please contact:

NovaGo Therapeutics AG

media@novagotx.com

www.novagotherapeutics.com 

SOURCE NovaGo Therapeutics

Share this article